Cerebral protection devices for transcatheter aortic valve replacement

Area of Science:

• Cardiology
• Neurology
• Interventional Cardiology

Background:

• Aortic stenosis is the most common heart valve disease in developed nations, with rising prevalence due to aging populations.
• Transcatheter aortic valve replacement (TAVR) is a primary treatment for severe aortic stenosis, increasingly used in younger, lower-risk patients.
• Cerebrovascular events (CVEs) remain a significant complication of TAVR, contributing to increased morbidity and mortality.

Purpose of the Study:

• To review the scientific evidence on cerebrovascular events (CVEs) following transcatheter aortic valve replacement (TAVR).
• To summarize the performance and outcomes of cerebral protection devices (CPDs) used during TAVR.
• To highlight the importance of CVE prevention as TAVR adoption expands.

Main Methods:

• Literature review of studies on CVEs after TAVR.
• Analysis of imaging studies indicating embolic etiology for most CVEs.
• Summary of data on the efficacy and safety of various cerebral protection devices (CPDs).

Main Results:

• The incidence of CVEs after TAVR ranges from 2.7% to 5.5% at 30 days.
• Most CVEs following TAVR are likely embolic in origin.
• Cerebral protection devices (CPDs) were developed to mitigate the risk of CVEs during TAVR procedures.

Conclusions:

• Cerebrovascular events (CVEs) are a critical concern in transcatheter aortic valve replacement (TAVR), necessitating effective prevention strategies.
• Cerebral protection devices (CPDs) represent a promising approach to reduce CVEs during TAVR.
• Further research and clinical assessment are crucial to optimize CVE prevention in the expanding TAVR population.